Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32800760
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Recomendaciones sobre el manejo de pacientes adultos con enfermedades reumáticas
en el contexto de la infección por SARS-CoV-2/COVID-19 Asociación Colombiana de
Reumatología
#MMPMID32800760
Saldarriaga Rivera LM
; Fernández Ávila D
; Bautista Molano W
; Jaramillo Arroyave D
; Bautista Ramírez AJ
; Díaz Maldonado A
; Hernán Izquierdo J
; Jáuregui E
; Latorre Muñoz MC
; Restrepo JP
; Segura Charry JS
Reumatol Clin (Engl Ed)
2020[Nov]; 16
(6
): 437-446
PMID32800760
show ga
OBJECTIVE: To produce recommendations for patients with rheumatological diseases
receiving immunomodulatory and immunosuppressive therapies (conventional drugs,
biologicals, and small molecules) during the COVID-19 pandemic. MATERIALS AND
METHODS: The recommendations were determined using the Delphi method as an
agreement tool. A panel of experts was formed, with academic backgrounds and
research experience in rheumatology. A literature search was conducted and 42
questions were generated. The level of agreement was made with 80% of approval by
the participants. RESULTS: A group of eleven rheumatologists from 7 cities in the
country participated. The response rate was 100% for the three consultation
rounds. In the first round, agreement was reached on 35 questions, on 37 in the
second round, and on 42 questions in the third round. CONCLUSION: The
recommendation for the majority of the pharmacological treatments used in
rheumatology is to continue with immunomodulatory or immunosuppressive therapies
in patients who do not have the infection, and to suspend it in patients with a
diagnosis of SARS-CoV-2/COVID-19.
|*Betacoronavirus
[MESH]
|*Pandemics
[MESH]
|Adult
[MESH]
|Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
[MESH]
|Antibodies, Monoclonal/adverse effects/therapeutic use
[MESH]
|Antimalarials/adverse effects/therapeutic use
[MESH]
|Antirheumatic Agents/adverse effects/*therapeutic use
[MESH]
|Biological Products/adverse effects/therapeutic use
[MESH]
free
free
free
